Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

NCT03165617 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4514

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: QIVc
BIOLOGICAL: Non-influenza Comparator Vaccine

Sponsor

Seqirus